In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?
Session

Event : HFA Discoveries

Topic : Acute Heart Failure: Pharmacotherapy

  • Session type : Industry Essentials
  • Date :
  • Sponsorered by Novartis Pharma AG

5 presentations in this session

Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?

Event : HFA Discoveries 2020

  • Session : Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?
  • Speaker : CS Lam (Singapore,SG), P Seferovic (Belgrade,RS), W Mullens (Genk,BE), M Guazzi (San Donato Milanese,IT)
  • Sponsorered by Novartis Pharma AG

Introduction

Event : HFA Discoveries 2020

  • Session : Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?
  • Speaker : CS Lam (Singapore,SG), P Seferovic (Belgrade,RS)
  • Sponsorered by Novartis Pharma AG

Cardiac remodelling in heart failure – the implications for patients.

Event : HFA Discoveries 2020

  • Session : Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?
  • Speaker : W Mullens (Genk,BE)
  • Sponsorered by Novartis Pharma AG

Cardiac remodelling in patients treated with sacubitril/valsartan – what have studies shown?

Event : HFA Discoveries 2020

  • Session : Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?
  • Speaker : M Guazzi (San Donato Milanese,IT)
  • Sponsorered by Novartis Pharma AG

Based on what we know today, what should be the foundational therapy for heart failure patients? Summary and Conclusion.

Event : HFA Discoveries 2020

  • Session : Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?
  • Speaker : CS Lam (Singapore,SG)
  • Sponsorered by Novartis Pharma AG

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are